Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 78.16M | 38.31M | 10.01M | 48.40M | 13.29M |
| Total Depreciation and Amortization | 31.00K | 30.00K | 30.00K | 31.00K | 30.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.33M | -49.08M | -11.14M | -59.63M | -14.21M |
| Change in Net Operating Assets | -8.06M | 7.82M | 639.00K | 9.58M | -2.64M |
| Cash from Operations | -200.00K | -2.92M | -466.00K | -1.63M | -3.54M |
| Capital Expenditure | -2.00K | -5.00K | -2.00K | 0.00 | -4.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.31M | -19.48M | -1.68M | 38.36M | -54.85M |
| Cash from Investing | 4.31M | -19.49M | -1.68M | 38.36M | -54.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.87M | -- | -4.01M | -361.00K | -371.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -78.00K | -10.36M | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.95M | -10.36M | -4.01M | -361.00K | -371.00K |
| Foreign Exchange rate Adjustments | -118.00K | 22.00K | -73.00K | 4.00K | 40.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.04M | -32.75M | -6.23M | 36.38M | -58.72M |